ImQuest BioSciences Expands In Vitro Toxicology Testing Services

March 6, 2017

FREDERICK, MD March 06, 2017 -- ImQuest BioSciences now offers validated assays to determine the toxic effects of small molecules and biologics on mitochondrial function, and are offered as a component of ImQuest's mechanism of toxicity assays. Understanding the mechanism of toxic effect is crucial to assessing the development potential of novel therapeutic entities. ImQuest also offers in vitro assays designed to understand how a drug is absorbed and distributed into the body, including pharmacokinetic studies and bioanalytical method development.

Director of Toxicology Services, Tracy Hartman commented, "Our mitochondrial toxicity assays have a broad range of applications, from studies of the effects of viral polymerase inhibitors on mitochondrial DNA synthesis, to antibiotic induced mitochondrial dysfunction, and the effect of anticancer therapeutics on mitochondrial respiration. They expand our offering of mechanism of cytotoxicity assays, which complement our cytotoxicity assessment assays."

"With our ToxiSENS platform, we can rapidly screen drug candidates for cytotoxicity and identify the mechanisms responsible for the toxic effects in a wide variety of human cells including blood cells, liver cells, kidney cells, heart cells and central nervous system cells. This allows us to assist our clients in understanding the risks of moving a product forward to human testing and rapidly identify issues that might cause a clients' compound to fail in animal and human testing, thereby enhancing their chances of successful drug development," added Robert W. Buckheit, Jr. Ph.D., President and Chief Scientific Officer.

For More information on ImQuest BioSciences ToxiSENS in vitro Toxicology services, visit http://imquestbio.com/programs/in-vitro-toxicology/.

About ImQuest BioSciences

ImQuest BioSciences is a leading preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of infectious disease, cancer and inflammatory diseases. ImQuest provides expert preclinical research services and compound screening to define the efficacy, mechanism of action and toxicity of pharmaceutical products and specializes in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs. The ImQuest team is committed to earning client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication.

Scientific Inquires and Business Development Contact

Robert W. Buckheit III Ph.D., Director Business Development, ImQuest BioSciences, Inc.

Robert.Buckheit@imquestbio.com

Return to Press Releases